Webster K Cavenee

List of Publications by Year
in descending order

200	51,153	4641	85	2500	196
papers	citations		h-index		g-index

203	203	203	47484
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Insights into the Mechanisms of Action of MDA-7/IL-24: A Ubiquitous Cancer-Suppressing Protein. International Journal of Molecular Sciences, 2022, 23, 72.	1.8	5
2	Immune evasion in HPV^{â^'}head and neck precancerâ€“cancer transition is driven by an aneuploid switch involving chromosome 9p loss. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	45
3	Pharmacological inhibition of MDA-9/Syntenin blocks breast cancer metastasis through suppression of IL-1Î². Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	16
4	Targeted AAVP-based therapy in a mouse model of human glioblastoma: a comparison of cytotoxic versus suicide gene delivery strategies. Cancer Gene Therapy, 2020, 27, 301-310.	2.2	26
5	Dual Regulation of Histone Methylation by mTOR Complexes Controls Glioblastoma Tumor Cell Growth via EZH2 and SAM. Molecular Cancer Research, 2020, 18, 1142-1152.	1.5	25
6	Lumefantrine, an antimalarial drug, reverses radiation and temozolomide resistance in glioblastoma. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 12324-12331.	3.3	28
7	Tumour predisposition and cancer syndromes as models to study geneâ€“environment interactions. Nature Reviews Cancer, 2020, 20, 533-549.	12.8	93
8	mTOR complex 2 is an integrator of cancer metabolism and epigenetics. Cancer Letters, 2020, 478, 1-7.	3.2	27
9	Codependency of Metabolism and Epigenetics Drives Cancer Progression: A Review. Acta Histochemica Et Cytochemica, 2020, 53, 1-10.	0.8	23
10	MDA-9/Syntenin (SDCBP): Novel gene and therapeutic target for cancer metastasis. Pharmacological Research, 2020, 155, 104695.	3.1	29
11	Oncogene Amplification in Growth Factor Signaling Pathways Renders Cancers Dependent on Membrane Lipid Remodeling. Cell Metabolism, 2019, 30, 525-538.e8.	7.2	130
12	mTORC2 links growth factor signaling with epigenetic regulation of iron metabolism in glioblastoma. Journal of Biological Chemistry, 2019, 294, 19740-19751.	1.6	23
13	Rethinking Glioblastoma Therapy: MDA-9/Syntenin Targeted Small Molecule. ACS Chemical Neuroscience, 2019, 10, 1121-1123.	1.7	12
14	Oncogenic mutations at the EGFR ectodomain structurally converge to remove a steric hindrance on a kinase-coupled cryptic epitope. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 10009-10018.	3.3	46
15	MDA-7/IL-24 regulates the miRNA processing enzyme DICER through downregulation of MITF. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 5687-5692.	3.3	24
16	Detection of early-stage hepatocellular carcinoma in asymptomatic HBsAg-seropositive individuals by liquid biopsy. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 6308-6312.	3.3	127
17	Inhibition of Nuclear PTEN Tyrosine Phosphorylation Enhances Glioma Radiation Sensitivity through Attenuated DNA Repair. Cancer Cell, 2019, 35, 504-518.e7.	7.7	102
18	Emerging Pharmacologic Targets in Cerebral Cavernous Malformation and Potential Strategies to Alter the Natural History of a Difficult Disease. JAMA Neurology, 2019, 76, 492.	4.5	36

#	Article	IF	Citations
19	Metabolic reprogramming in the pathogenesis of glioma: Update. Neuropathology, 2019, 39, 3-13.	0.7	38
20	Blockade of a Laminin-411â€“Notch Axis with CRISPR/Cas9 or a Nanobioconjugate Inhibits Glioblastoma Growth through Tumor-Microenvironment Cross-talk. Cancer Research, 2019, 79, 1239-1251.	0.4	61
21	FHL2 interacts with EGFR to promote glioblastoma growth. Oncogene, 2018, 37, 1386-1398.	2.6	25
22	Fluorescence Molecular Tomography for In Vivo Imaging of Glioblastoma Xenografts. Journal of Visualized Experiments, 2018, , .	0.2	4
23	Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE. Clinical Cancer Research, 2018, 24, 737-743.	3.2	154
24	Consensus report of the 8 and 9th Weinman Symposia on Gene x Environment Interaction in carcinogenesis: novel opportunities for precision medicine. Cell Death and Differentiation, 2018, 25, 1885-1904.	5.0	31
25	MDA-9/Syntenin regulates protective autophagy in anoikis-resistant glioma stem cells. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 5768-5773.	3.3	91
26	Regulation of protective autophagy in anoikis-resistant glioma stem cells by SDCBP/MDA-9/Syntenin. Autophagy, 2018, 14, 1845-1846.	4.3	30
27	Reply to Yoshida: Delineating critical roles of MDA-9 in protective autophagy-mediated anoikis resistance in human glioma stem cells. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E7654-E7655.	3.3	2
28	Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity. Nature, 2017, 543, 122-125.	13.7	530
29	Selective replication of oncolytic virus M1 results in a bystander killing effect that is potentiated by Smac mimetics. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 201701002.	3.3	33
30	Inhibition of radiation-induced glioblastoma invasion by genetic and pharmacological targeting of MDA-9/Syntenin. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 370-375.	3.3	79
31	Glioblastoma cellular cross-talk converges on NF-Î²B to attenuate EGFR inhibitor sensitivity. Genes and Development, 2017, 31, 1212-1227.	2.7	53
32	Precision cancer therapy is impacted by oncogene-dependent epigenome remodeling. Npj Precision Oncology, 2017, 1, 1.	2.3	90
33	Going viral? Linking the etiology of human prostate cancer to the <scp>PCA</scp> 3 long noncoding <scp>RNA</scp> and oncogenic viruses. EMBO Molecular Medicine, 2017, 9, 1327-1330.	3.3	10
34	Single-Cell Phosphoproteomics Resolves Adaptive Signaling Dynamics and Informs Targeted Combination Therapy in Glioblastoma. Cancer Cell, 2016, 29, 563-573.	7.7	140
35	The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathologica, 2016, 131, 803-820.	3.9	12,144
36	An LXR-Cholesterol Axis Creates a Metabolic Co-Dependency for Brain Cancers. Cancer Cell, 2016, 30, 683-693.	7.7	237

#	Article	IF	Citations
37	mTORC2 activity in brain cancer: Extracellular nutrients are required to maintain oncogenic signaling. BioEssays, 2016, 38, 839-844.	1.2	16
38	Simultaneous blockade of interacting CK2 and EGFR pathways by tumor-targeting nanobioconjugates increases therapeutic efficacy against glioblastoma multiforme. Journal of Controlled Release, 2016, 244, 14-23.	4.8	40
39	Cancer metabolism as a central driving force of glioma pathogenesis. Brain Tumor Pathology, 2016, 33, 161-168.	1.1	38
40	mTORC2 and Metabolic Reprogramming in GBM: at the Interface of Genetics and Environment. Brain Pathology, 2015, 25, 755-759.	2.1	26
41	Orthogonal targeting of EGFRvIII expressing glioblastomas through simultaneous EGFR and PLK1 inhibition. Oncotarget, 2015, 6, 11751-11767.	0.8	9
42	Mutational landscape of gastric adenocarcinoma in Chinese: Implications for prognosis and therapy. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 1107-1112.	3.3	137
43	A Urokinase Receptorâ€“Bim Signaling Axis Emerges during EGFR Inhibitor Resistance in Mutant EGFR Glioblastoma. Cancer Research, 2015, 75, 394-404.	0.4	48
44	Glucose-dependent acetylation of Rictor promotes targeted cancer therapy resistance. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 9406-9411.	3.3	96
45	PRUNE2 is a human prostate cancer suppressor regulated by the intronic long noncoding RNA PCA3. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 8403-8408.	3.3	226
46	Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma. Nature Reviews Cancer, 2015, 15, 302-310.	12.8	305
47	EGFR Mutation Promotes Glioblastoma through Epigenome and Transcription Factor Network Remodeling. Molecular Cell, 2015, 60, 307-318.	4.5	161
48	mTORC2 dictates Warburg effect and drug resistance. Cell Cycle, 2014, 13, 1053-1054.	1.3	16
49	Efficient synthesis of chloro-derivatives of sialosyllactosylceramide, and their enhanced inhibitory effect on epidermal growth factor receptor activation. Oncology Letters, 2014, 7, 933-940.	0.8	7
50	Glioblastoma: From Molecular Pathology to Targeted Treatment. Annual Review of Pathology: Mechanisms of Disease, 2014, 9, 1-25.	9.6	427
51	Targeted Therapy Resistance Mediated by Dynamic Regulation of Extrachromosomal Mutant EGFR DNA. Science, 2014, 343, 72-76.	6.0	460
52	Suppression of MicroRNA-9 by Mutant EGFR Signaling Upregulates FOXP1 to Enhance Glioblastoma Tumorigenicity. Cancer Research, 2014, 74, 1429-1439.	0.4	59
53	mTORC2 in the center of cancer metabolic reprogramming. Trends in Endocrinology and Metabolism, 2014, 25, 364-373.	3.1	110
54	EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis. Journal of Clinical Investigation, 2014, 124, 3741-3756.	3.9	82

#	Article	IF	Citations
55	Genome-wide shRNA screen revealed integrated mitogenic signaling between dopamine receptor D2 (DRD2) and epidermal growth factor receptor (EGFR) in glioblastoma. Oncotarget, 2014, 5, 882-893.	0.8	127
56	Emerging function of mTORC2 as a core regulator in glioblastoma: metabolic reprogramming and drug resistance. Cancer Biology and Medicine, 2014, 11, 255-63.	1.4	44
57	Nuclear EGFRvIIIâ€STAT5b complex contributes to glioblastoma cell survival by direct activation of the Bclâ€XL promoter. International Journal of Cancer, 2013, 132, 509-520.	2.3	41
58	mTOR Complex 2 Controls Glycolytic Metabolism in Glioblastoma through FoxO Acetylation and Upregulation of c-Myc. Cell Metabolism, 2013, 18, 726-739.	7.2	351
59	The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas. Clinical Cancer Research, 2013, 19, 5722-5732.	3.2	46
60	A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments. Carcinogenesis, 2013, 34, 725-738.	1.3	86
61	De-Repression of PDGFRÎ² Transcription Promotes Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in Glioblastoma Patients. Cancer Discovery, 2013, 3, 534-547.	7.7	126
62	EGFR Mutation-Induced Alternative Splicing of Max Contributes to Growth of Glycolytic Tumors in Brain Cancer. Cell Metabolism, 2013, 17, 1000-1008.	7.2	130
63	A Kinome-Wide RNAi Screen in Drosophila Glia Reveals That the RIO Kinases Mediate Cell Proliferation and Survival through TORC2-Akt Signaling in Glioblastoma. PLoS Genetics, 2013, 9, e1003253.	1.5	114
64	Arsenic reverses glioblastoma resistance to mTOR-targeted therapies. Cell Cycle, 2013, 12, 1473-1474.	1.3	9
65	PML mediates glioblastoma resistance to mammalian target of rapamycin (mTOR)-targeted therapies. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 4339-4344.	3.3	60
66	Therapeutic resistance in cancer: microRNA regulation of EGFR signaling networks. Cancer Biology and Medicine, 2013, 10, 192-205.	1.4	45
67	Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 14164-14169.	3.3	97
68	Phosphorylation of dedicator of cytokinesis 1 (Dock180) at tyrosine residue Y722 by Src family kinases mediates EGFRvIII-driven glioblastoma tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 3018-3023.	3.3	88
69	Genetic Driver Events in Premalignancy: LOH Validated for Marking the Risk of Oral Cancer. Cancer Prevention Research, 2012, 5, 1073-1074.	0.7	3
70	Emerging insights into the molecular and cellular basis of glioblastoma. Genes and Development, 2012, 26, 756-784.	2.7	463
71	Analysis of Phosphotyrosine Signaling in Glioblastoma Identifies STAT5 as a Novel Downstream Target of Î”EGFR. Journal of Proteome Research, 2011, 10, 1343-1352.	1.8	44
72	Heterogeneity Maintenance in Glioblastoma: A Social Network. Cancer Research, 2011, 71, 4055-4060.	0.4	386

#	Article	IF	Citations
73	MicroRNA-138 Modulates DNA Damage Response by Repressing Histone H2AX Expression. Molecular Cancer Research, 2011, 9, 1100-1111.	1.5	146
74	Guanylate binding protein 1 is a novel effector of EGFR-driven invasion in glioblastoma. Journal of Experimental Medicine, 2011, 208, 2657-2673.	4.2	65
75	Oncogenic EGFR Signaling Activates an mTORC2â€“NF-Î²B Pathway That Promotes Chemotherapy Resistance. Cancer Discovery, 2011, 1, 524-538.	7.7	275
76	Crosstalk between the urokinase-type plasminogen activator receptor and EGF receptor variant III supports survival and growth of glioblastoma cells. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 15984-15989.	3.3	54
77	Activation of Src induces mitochondrial localisation of de2-7EGFR (EGFRvIII) in glioma cells: implications for glucose metabolism. Journal of Cell Science, 2011, 124, 2938-2950.	1.2	35
78	Systemic combinatorial peptide selection yields a non-canonical iron-mimicry mechanism for targeting tumors in a mouse model of human glioblastoma. Journal of Clinical Investigation, 2011, 121, 161-173.	3.9	141
79	Activation of Rac1 by Src-dependent phosphorylation of Dock180Y1811 mediates PDGFRÎ±-stimulated glioma tumorigenesis in mice and humans. Journal of Clinical Investigation, 2011, 121, 4670-4684.	3.9	105
80	Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations. Chinese Journal of Cancer, 2011, 30, 5-12.	4.9	116
81	Targeting EGFR Induced Oxidative Stress by PARP1 Inhibition in Glioblastoma Therapy. PLoS ONE, 2010, 5, e10767.	1.1	59
82	Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes and Development, 2010, 24, 1731-1745.	2.7	454
83	Mutant EGFR is required for maintenance of glioma growth in vivo, and its ablation leads to escape from receptor dependence. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 2616-2621.	3.3	63
84	KLF6 Gene and Early Melanoma Development in a Collagen I-Rich Extracellular Environment. Journal of the National Cancer Institute, 2010, 102, 1131-1147.	3.0	12
85	Escape from targeted inhibition: The dark side of kinase inhibitor therapy. Cell Cycle, 2010, 9, 1661-1662.	1.3	12
86	Phosphotyrosine signaling analysis of site-specific mutations on EGFRvIII identifies determinants governing glioblastoma cell growth. Molecular BioSystems, 2010, 6, 1227.	2.9	40
87	Antibodies specifically targeting a locally misfolded region of tumor associated EGFR. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 5082-5087.	3.3	69
88	Fyn and Src Are Effectors of Oncogenic Epidermal Growth Factor Receptor Signaling in Glioblastoma Patients. Cancer Research, 2009, 69, 6889-6898.	0.4	136
89	EGFRvIII and DNA Double-Strand Break Repair: A Molecular Mechanism for Radioresistance in Glioblastoma. Cancer Research, 2009, 69, 4252-4259.	0.4	232
90	A Drosophila Model for EGFR-Ras and PI3K-Dependent Human Glioma. PLoS Genetics, 2009, 5, e1000374.	1.5	179

#	Article	IF	Citations
91	Genome-wide mapping and analysis of active promoters in mouse embryonic stem cells and adult organs. Genome Research, 2008, 18, 46-59.	2.4	111
92	Feedback Circuit among INK4 Tumor Suppressors Constrains Human Glioblastoma Development. Cancer Cell, 2008, 13, 355-364.	7.7	109
93	Development of a Real-time RT-PCR Assay for Detecting EGFRvIII in Glioblastoma Samples. Clinical Cancer Research, 2008, 14, 488-493.	3.2	91
94	Stem Cells for Treating Glioblastoma: How Close to Reality?. Neuro-Oncology, 2008, 11, 101-101.	0.6	8
95	Guilt by association: PAX3-FOXO1 regulates gene expression through selective destabilization of the EGR1 transcription factor. Cell Cycle, 2008, 7, 837-841.	1.3	16
96	Uncovering Therapeutic Targets FOR Glioblastoma: A Systems Biology Approach. Cell Cycle, 2007, 6, 2750-2754.	1.3	63
97	The Efficacy of Epidermal Growth Factor Receptorâ€“Specific Antibodies against Glioma Xenografts Is Influenced by Receptor Levels, Activation Status, and Heterodimerization. Clinical Cancer Research, 2007, 13, 1911-1925.	3.2	64
98	PAX3-FOXO1 controls expression of the p57Kip2 cell-cycle regulator through degradation of EGR1. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 18085-18090.	3.3	50
99	Synergistic cytotoxicity through the activation of multiple apoptosis pathways in human glioma cells induced by combined treatment with ionizing radiation and tumor necrosis factorâ€“related apoptosis-inducing ligand. Journal of Neurosurgery, 2007, 106, 407-416.	0.9	24
100	Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 12867-12872.	3.3	365
101	Therapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutantâ€“dependent lung carcinomas. Journal of Clinical Investigation, 2007, 117, 346-352.	3.9	44
102	Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes and Development, 2007, 21, 2683-2710.	2.7	1,952
103	The 2007 WHO Classification of Tumours of the Central Nervous System. Acta Neuropathologica, 2007, 114, 97-109.	3.9	9,898
104	Transgenic mice expressing PAX3-FKHR have multiple defects in muscle development, including ectopic skeletal myogenesis in the developing neural tube. Transgenic Research, 2006, 15, 595-614.	1.3	17
105	Identification of EGFRvIII-derived CTL Epitopes Restricted by HLA A0201 for Dendritic Cell Based Immunotherapy of Gliomas. Journal of Neuro-Oncology, 2006, 76, 23-30.	1.4	53
106	The PTEN and INK4A/ARF tumor suppressors maintain myelolymphoid homeostasis and cooperate to constrain histiocytic sarcoma development in humans. Cancer Cell, 2006, 9, 379-390.	7.7	65
107	Mammalian Target of Rapamycin Inhibition Promotes Response to Epidermal Growth Factor Receptor Kinase Inhibitors in PTEN-Deficient and PTEN-Intact Glioblastoma Cells. Cancer Research, 2006, 66, 7864-7869.	0.4	231
108	PCAF Modulates PTEN Activity. Journal of Biological Chemistry, 2006, 281, 26562-26568.	1.6	183

#	Article	IF	Citations
109	Cellular transformation by the MSP58 oncogene is inhibited by its physical interaction with the PTEN tumor suppressor. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 2703-2706.	3.3	109
110	Treatment of Human Tumor Xenografts with Monoclonal Antibody 806 in Combination with a Prototypical Epidermal Growth Factor Receptorâ€"Specific Antibody Generates Enhanced Antitumor Activity. Clinical Cancer Research, 2005, 11, 6390-6399.	3.2	103
111	PTEN: A Novel Anti-oncogenic Function Independent of Phosphatase Activity. Cell Cycle, 2005, 4, 540-542.	1.3	26
112	Molecular Determinants of the Response of Glioblastomas to EGFR Kinase Inhibitors. New England Journal of Medicine, 2005, 353, 2012-2024.	13.9	1,376
113	Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Molecular Cancer Therapeutics, 2005, 4, 101-12.	1.9	176
114	Alix/AIP1 Antagonizes Epidermal Growth Factor Receptor Downregulation by the Cbl-SETA/CIN85 Complex. Molecular and Cellular Biology, 2004, 24, 8981-8993.	1.1	108
115	Immunohistochemical analysis of the mutant epidermal growth factor, Î"EGFR, in glioblastoma. Brain Tumor Pathology, 2004, 21, 53-56.	1.1	112
116	Disruption of forkhead transcription factor (FOXO) family members in mice reveals their functional diversification. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 2975-2980.	3.3	606
117	Methylation Profiling Identifies Epigenetic Markers for High-grade Gliomas. Cancer Genomics and Proteomics, 2004, 1, 209-214.	1.0	3
118	The recessive nature of dominance. Genes Chromosomes and Cancer, 2003, 38, 322-325.	1.5	2
119	Platelet-Derived Growth Factor-B Enhances Glioma Angiogenesis by Stimulating Vascular Endothelial Growth Factor Expression in Tumor Endothelia and by Promoting Pericyte Recruitment. American Journal of Pathology, 2003, 162, 1083-1093.	1.9	304
120	A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 8164-8169.	3.3	447
121	Epidermal growth factor receptor signaling intensity determines intracellular protein interactions, ubiquitination, and internalization. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 6505-6510.	3.3	141
122	A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 639-644.	3.3	158
123	Angiopoietin-2 induces human glioma invasion through the activation of matrix metalloprotease-2. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 8904-8909.	3.3	146
124	Preparing for Serendipity. Cancer Biology and Therapy, 2003, 2, 213-215.	1.5	0
125	Genetics and new approaches to cancer therapy. Carcinogenesis, 2002, 23, 683-686.	1.3	22
126	The WHO Classification of Tumors of the Nervous System. Journal of Neuropathology and Experimental Neurology, 2002, 61, 215-225.	0.9	1,615

#	Article	IF	Citations
127	Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene. International Journal of Cancer, 2002, 98, 398-408.	2.3	119
128	A novel seven transmembrane receptor induced during the early steps of astrocyte differentiation identified by differential expression. Journal of Neurochemistry, 2002, 81, 575-588.	2.1	4
129	Regulation of insulin action and pancreatic Î²-cell function by mutated alleles of the gene encoding forkhead transcription factor Foxo1. Nature Genetics, 2002, 32, 245-253.	9.4	597
130	Muscling in on rhabdomyosarcoma. Nature Medicine, 2002, 8, 1200-1201.	15.2	7
131	CD95â€mediated Apoptosis of Human Glioma Cells: Modulation by Epidermal Growth Factor Receptor Activity. Brain Pathology, 2002, 12, 12-20.	2.1	36
132	Mutant epidermal growth factor receptor signaling down-regulates p27 through activation of the phosphatidylinositol 3-kinase/Akt pathway in glioblastomas. Cancer Research, 2002, 62, 6764-9.	0.4	152
133	Malignant glioma: genetics and biology of a grave matter. Genes and Development, 2001, 15, 1311-1333.	2.7	1,064
134	The Protein Tyrosine Phosphatase TCPTP Suppresses the Tumorigenicity of Glioblastoma Cells Expressing a Mutant Epidermal Growth Factor Receptor. Journal of Biological Chemistry, 2001, 276, 46313-46318.	1.6	66
135	Human glioblastoma xenografts overexpressing a tumor-specific mutant epidermal growth factor receptor sensitized to cisplatin by the AG1478 tyrosine kinase inhibitor. Journal of Neurosurgery, 2001, 95, 472-479.	0.9	74
136	Aberrant CpG-island methylation has non-random and tumour-typeâ€"specific patterns. Nature Genetics, 2000, 24, 132-138.	9.4	1,292
137	IGF-I receptor signaling in a prostatic cancer cell line with a PTEN mutation. Oncogene, 2000, 19, 2687-2694.	2.6	75
138	Analysis of the p300/CBP-Associated Factor (PCAF) gene in astrocytic tumors. Journal of Neuro-Oncology, 2000, 46, 17-22.	1.4	11
139	Aberrant methylation of genes in low-grade astrocytomas. Brain Tumor Pathology, 2000, 17, 49-56.	1.1	59
140	Identification and Characterization of Novel Genes Located at the t(1;15)(p36.2;q24) Translocation Breakpoint in the Neuroblastoma Cell Line NGP. Genomics, 2000, 64, 195-202.	1.3	22
141	PTEN gene transfer in human malignant glioma: sensitization to irradiation and CD95L-induced apoptosis. Oncogene, 1999, 18, 3936-3943.	2.6	102
142	The retinoblastoma tumor suppressor inhibits cellular proliferation through two distinct mechanisms: inhibition of cell cycle progression and induction of cell death. Oncogene, 1999, 18, 5239-5245.	2.6	57
143	Causes of drug resistance and novel therapeutic opportunities for the treatment of glioblastoma. Drug Resistance Updates, 1999, 2, 30-37.	6.5	6
144	A New Tool for the Rapid Cloning of Amplified and Hypermethylated Human DNA Sequences from Restriction Landmark Genome Scanning Gels. Genomics, 1999, 58, 254-262.	1.3	74

#	Article	IF	Citations
145	Identification and Validation of Tumor Suppressor Genes. Molecular Cell Biology Research Communications: MCBRC: Part B of Biochemical and Biophysical Research Communications, 1999, 2, 1-10.	1.7	14
146	Expression of vascular endothelial growth factor in human brain tumors. Acta Neuropathologica, 1998, 96, 453-462.	3.9	93
147	Cloning and Characterization of Three Human Forkhead Genes That Comprise an FKHR-like Gene Subfamily. Genomics, 1998, 47, 187-199.	1.3	319
148	Host Microvasculature Influence on Tumor Vascular Morphology and Endothelial Gene Expression. American Journal of Pathology, 1998, 153, 1239-1248.	1.9	101
149	Multiple G1 Regulatory Elements Control the Androgen-dependent Proliferation of Prostatic Carcinoma Cells. Journal of Biological Chemistry, 1998, 273, 20213-20222.	1.6	165
150	In vitroloss of heterozygosity targets thePTEN/MMAC1gene in melanoma. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 9418-9423.	3.3	90
151	The Enhanced Tumorigenic Activity of a Mutant Epidermal Growth Factor Receptor Common in Human Cancers Is Mediated by Threshold Levels of Constitutive Tyrosine Phosphorylation and Unattenuated Signaling. Journal of Biological Chemistry, 1997, 272, 2927-2935.	1.6	502
152	Advances in the molecular genetics of gliomas. Current Opinion in Oncology, 1997, 9, 215-222.	1.1	56
153	Further Evidence For Ultraviolet Light Induction Of CDKN2(p16INK4) Mutations In Sporadic Melanoma In Vivo. Journal of Investigative Dermatology, 1997, 108, 950.	0.3	14
154	Point mutations can inactivate in vitro and in vivo activities of p16INK4a/CDKN2A in human glioma. Oncogene, 1997, 14, 603-609.	2.6	32
155	The expression of RET and its multiple splice forms in developing human kidney. Oncogene, 1997, 14, 1811-1818.	2.6	35
156	Functional analysis of wild-type and malignant glioma derived CDKN2AÎ² alleles: Evidence for an RB-independent growth suppressive pathway. Oncogene, 1997, 15, 2013-2020.	2.6	33
157	Expression and distribution of vascular endothelial growth factor protein in human brain tumors. Acta Neuropathologica, 1997, 93, 109-117.	3.9	169
158	cAMP Effects on Myogenic Gene Expression in Rhabdomyosarcoma Cells. Experimental Cell Research, 1996, 227, 55-62.	1.2	5
159	A common region of loss of heterozygosity in Wilms' tumor and embryonal rhabdomyosarcoma distal to the D11S988 locus on chromosome 11p15.5. Human Genetics, 1996, 97, 163-170.	1.8	67
160	Molecular Biology of Malignant Degeneration of Astrocytoma. Pediatric Neurosurgery, 1996, 24, 41-49.	0.4	16
161	Detection of the t(2;13) chromosomal translocation in alveolar rhabdomyosarcoma using the reverse transcriptase-polymerase chain reaction. , 1996, 16, 254-260.		36
162	Enhanced Tumorigenic Behavior of Glioblastoma Cells Expressing a Truncated Epidermal Growth Factor Receptor Is Mediated through the Ras-Shc-Grb2 Pathway. Journal of Biological Chemistry, 1996, 271, 25639-25645.	1.6	147

#	Article	IF	Citations
163	Population variation at the polymorphic ApaLI restriction enzyme site in intron 5 of the WT1 gene. Clinical Genetics, 1996, 50, 555-557.	1.0	0
164	EGFR gene amplification - rearrangement in human glioblastomas. International Journal of Cancer, 1995, 62, 145-148.	2.3	106
165	A constitutional bws-related t(11;16) chromosome translocation occurring in the same region of chromosome 16 implicated in wilms' tumors. Genes Chromosomes and Cancer, 1995, 12, 1-7.	1.5	24
166	The t(II; 22)(pI5.5; qII.23) in a retroperitoneal rhabdoid tumor also includes a regional deletion distal to CRYBB2 on 22q. Genes Chromosomes and Cancer, 1995, 13, 145-150.	1.5	17
167	Thep53 gene and its role in human brain tumors. Glia, 1995, 15, 308-327.	2.5	172
168	p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3. Nature Medicine, 1995, 1, 570-577.	15.2	415
169	Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics, 1994, 40, 360-369.	1.2	554
170	A new highly polymorphic DNA restriction site marker in the 5? region of the human tyrosine hydroxylase gene (TH) detecting loss of heterozygosity in human embryonal rhabdomyosarcoma. Human Genetics, 1994, 93, 349-350.	1.8	13
171	Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells. Nature Genetics, 1994, 8, 171-176.	9.4	313
172	Molecular Sublocalization and Characterization of the 11;22 Translocation Breakpoint in a Malignant Rhabdoid Tumor. Genomics, 1994, 19, 433-440.	1.3	21
173	Mutation and expression of the p53 gene in malignant melanoma cell lines. International Journal of Cancer, 1993, 54, 693-699.	2.3	83
174	Homozygous inactivation ofWTI in a Wilms' tumor associated with the WAGR syndrome. Genes Chromosomes and Cancer, 1993, 7, 131-136.	1.5	28
175	Tumors and developmental anomalies associated with Wilms tumor. Medical and Pediatric Oncology, 1993, 21, 199-204.	1.0	5
176	Loss of heterozygosity in malignant gliomas involves at least three distinct regions on chromosome 10. Human Genetics, 1993, 92, 169-74.	1.8	115
177	Characterization of polymorphic and monomorphic loci for Chromosome 11p15.5. Mammalian Genome, 1993, 4, 451-453.	1.0	0
178	A Genetic Linkage Map with 29 Loci Spanning Human Chromosome 13q. Genomics, 1993, 16, 515-519.	1.3	1
179	Accumulation of genetic defects during astrocytoma progression. Cancer, 1992, 70, 1788-1793.	2.0	51
180	Genetics of the malignant progression of astrocytoma. Journal of Cellular Biochemistry, 1991, 46, 3-8.	1.2	37

#	Article	IF	Citations
181	Microdissection of chromosome band 11 p 15.5: Characterization of probes mapping distal to theHBBC locus. Genes Chromosomes and Cancer, 1991, 3, 108-116.	1.5	14
182	Recessive mutations in the causation of human cancer. Cancer, 1991, 67, 2431-2435.	2.0	10
183	Molecular Genetics in the Pathology and Diagnosis of Retinoblastoma. Brain Pathology, 1990, 1, 25-32.	2.1	14
184	Genetic and Epigenetic Losses of Heterozygosity in Cancer Predisposition and Progression. Advances in Cancer Research, 1990, 54, 25-62.	1.9	71
185	Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping. Nature, 1990, 343, 774-778.	13.7	1,279
186	Loss of genetic information in central nervous system tumors common to children and young adults. Genes Chromosomes and Cancer, 1990, 2, 94-102.	1.5	103
187	Structural alterations at the putative retinoblastoma locus in some human leukemias and preleukemia. Cancer Genetics and Cytogenetics, 1990, 49, 15-23.	1.0	25
188	Molecular differential pathology of rhabdomyosarcoma. Genes Chromosomes and Cancer, 1989, 1, 23-35.	1.5	205
189	Familial predisposition to Wilms' tumour does not map to the short arm of chromosome 11. Nature, 1988, 336, 374-376.	13.7	251
190	Retinoblastoma and the progression of tumor genetics. Trends in Genetics, 1988, 4, 125-128.	2.9	79
191	Tumor suppressors: Recessive mutations that lead to cancer. Cell, 1988, 53, 172-173.	13.5	117
192	Tissue-Specific and Developmentally Regulated Transcription of the Insulin-Like Growth Factor 2 Gene. DNA and Cell Biology, 1987, 6, 283-295.	5.1	159
193	Retinoblastoma and Osteosarcoma: The Prototypic Cancer Family. Pediatrics International, 1987, 29, 526-533.	0.2	8
194	Recessive mutant genes predisposing to human cancer. Mutation Research - Reviews in Genetic Toxicology, 1986, 168, 3-14.	3.0	97
195	The genetic basis of neoplasia: the retinoblastoma paradigm. Trends in Genetics, 1986, 2, 299-300.	2.9	14
196	Prediction of Familial Predisposition to Retinoblastoma. New England Journal of Medicine, 1986, 314, 1201-1207.	13.9	115
197	Loss of heterozygosity in three embryonal tumours suggests a common pathogenetic mechanism. Nature, 1985, 316, 330-334.	13.7	535
198	Homozygosity of Chromosome 13 in Retinoblastoma. New England Journal of Medicine, 1984, 310, 550-553.	13.9	278

#	Article	IF	Citations
199	Characterization of dominant hamster cell mutants resistant to oxygenated sterols. Somatic Cell Genetics, 1982, 8, 557-574.	2.7	4
200	Elevation of HeLa cell 3-hydroxy-3-methylglutaryl coenzyme a reductase activity by glucocorticoids: Possible relationship to the cell cycle. Journal of Cellular Physiology, 1979, 98, 199-211.	2.0	26